Sanofi S.A., FR0000120578

Sanofi expands antibody alliance. Sanofi stock gains 1.39 percent

Published on 10/06/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi pays USD 1.00 billion upfront, with USD 7.00 billion possible. Sanofi stock stands at EUR 71.51 on October 6, 2026 versus EUR 70.53, plus 1.39 percent.

Bauhaus geometric poster with abstract stylized molecular structure in violet and cyan on white background with bold sans-serif PHARMACIE PARIS text — Sanofi FR0000120578 Bauhaus-style poster with abstract molecular structure in violet-cyan-white reading PHARMACIE PARIS, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) was trading at EUR 71.51 at Lang & Schwarz on October 6, 2026 at 11:48 a.m. CEST, plus 1.39 percent versus the prior close of EUR 70.53. As Reuters reported on October 1, 2026, Sanofi and Regeneron expanded their antibody collaboration in a deal with up to USD 8.00 billion in potential payments.

Alliance adds four antibody programs

The agreement gives Sanofi access to four long-acting antibody programs targeting interleukin-13, interleukin-4xinterleukin-13, interleukin-4 and interleukin-4 receptor alpha. According to Regeneron on October 1, 2026, Sanofi will pay USD 1.00 billion upfront and may pay up to an additional USD 7.00 billion in development, regulatory and commercial milestones.

The companies will share development and commercialization costs and split future profits 50:50 globally. One antibody is already in a phase 1 study, while the other three are expected to enter clinical studies in 2027, leaving the commercial value dependent on clinical and regulatory progress.

Second-quarter growth supports the pipeline

Sanofi reported second-quarter 2026 net sales of EUR 11.60 billion, up 17.80 percent from the prior-year quarter, while business earnings per share increased 33.30 percent. ScanX reported these figures for the quarter ended June 30, 2026, alongside a 3.80 percentage-point expansion in business operating income margin.

The operating picture was mixed across divisions: Dupixent sales exceeded EUR 5.00 billion and rose 37.00 percent year over year, while vaccine sales fell 5.00 percent to EUR 1.15 billion in the second quarter. That contrast makes pipeline execution and product launches important counters to seasonal vaccine pressure.

Analyst target stays above the quote

Markets Insider reported on October 1, 2026, that Jefferies maintained a Buy rating and a EUR 100.00 price target. The target lies 39.86 percent above the EUR 71.51 Lang & Schwarz price, a gap that reflects both the value assigned to Sanofi's growth pipeline and the risks attached to clinical development.

Third-quarter results set for October 30

Sanofi's investor-relations calendar lists third-quarter 2026 results for October 30, 2026, with a management presentation and question-and-answer session, according to Sanofi. The next report will test whether the second-quarter growth rate can offset the expected seasonal weakness in vaccines.

Sanofi was trading at EUR 71.51 at Lang & Schwarz on October 6, 2026 at 11:48 a.m. CEST, up 1.39 percent versus the EUR 70.53 prior close. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.